Across TCGA pan-cancer cohorts, MIR5691 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MIR5691’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where MIR5691 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR5691 is over-expressed in tumor.
BRCA and LUAD are the cancer types where MIR5691 tumor–normal differential expression is most reproducible.